肝病血瘀证与肝功能肝纤维化标志物的关系

测定３０例肝病血瘀证、３２例非血瘀证患者及２０例正常人肝功能和血清ＰＣⅢ、ＬＮ、ＨＡ含量。结果显示ＨＢＶ感染复制标志血瘀证与非血瘀证均表现较高的阳性率，两者比较无差异。Ｔ－ＢＩＬ升高及Ａ／Ｇ降低，血瘀证患者显著高于非血瘀证（Ｐ＜０．０５～０．０１）。血瘀证患者血清ＨＡ、ＬＮ含量明显高于非血瘀证患者及正常人，后两者无显著差异；ＰＣⅢ虽有上述变化趋势，但无统计学意义。提示：ＡＬＧ下降或倒置及血清ＨＡ、ＬＮ的含量，可做为慢性肝病血瘀证辨证的客观指标     

消痰和中方对慢性胰腺炎大鼠胰腺纤维化形成及相关蛋白表达的干预作用

目的观察消痰和中方对慢性胰腺炎模型大鼠胰腺纤维化形成及相关蛋白表达的影响,探讨其作用机制。方法24只Wistar大鼠随机分为正常组、模型组、胰酶组和中药组,每组6只。采用DDC溶液腹腔注射方法造模,其中胰酶组、中药组大鼠分别予胰酶、消痰和中方灌胃,定期测量大鼠体质量。4周后处死大鼠,取胰腺行病理检测及层黏连蛋白、基质金属蛋白酶-1的检测。结果经 DDC 溶液腹腔注射的大鼠,胰腺组织中均可见不同程度的纤维化及炎症细胞浸润。中药组大鼠在一般情况、体质量变化、胰腺病理切片评分及层黏连蛋白、基质金属蛋白酶-1表达方面均优于模型组,差异有统计学意义(P＜0.05)。结论消痰和中方能有效改善慢性胰腺炎大鼠一般情况,抑制胰腺纤维化形成。其作用机制可能与降低胰腺层黏连蛋白、增强基质金属蛋白酶-1的表达有关。     

软肝化纤汤联合恩替卡韦治疗慢性乙型肝炎后肝纤维化(肝郁脾虚)随机平行对照研究

[目的]观察软肝化纤汤联合恩替卡韦治疗慢性乙型肝炎后肝纤维化(肝郁脾虚)疗效。[方法]使用随机平行对照方法,将112例门诊患者按就诊顺序号方法随机分为两组。对照组56例恩替卡韦,0.5mg/次,1次/d,视耐受、年龄、病情等酌情调整剂量。治疗组56例软肝化纤汤(甘草炙6g,片姜黄、三七、龙葵、郁金、柴胡醋各10g,绞股蓝、赤芍、白花蛇舌草各15g,丹参、党参各20g,鳖甲30g),1剂/d,水煎400mL,早晚口服;恩替卡韦治疗同对照组。连续治疗6个月为1疗程。观测临床表现、血清白蛋白(ALB)、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBiL)、Ⅲ型前胶原肽(PⅢP)、Ⅳ型胶原(Ⅳ-C)、层黏连蛋白(LN)、透明质酸(HA)、不良反应。治疗1疗程(6个月),判定疗效。[结果]ALB、AST、ALT、TBiL两组均有改善(P<0.01),AST、ALT、TBiL治疗组改善优于对照组(P<0.01),ALB两组间无明显差异(P>0.05)。PⅢP、Ⅳ-C、LN、HA两组均有改善(P<0.01),治疗组改善优于对照组(P<0.01)。[结论]软肝化纤汤联合恩替卡韦慢性乙型肝炎后肝纤维化(肝郁脾虚),疗效满意,无严重不良反应,值得推广。     

Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases

Summary Laminin, the major glycoprotein component of basement membrane, promotes the malignant phenotype. Cells which are adherent to laminin are more malignant than the non-adherent cells and in certain tumor cells, the number of laminin receptors is positively correlated with malignancy. Laminin also increases collagenase IV activity, an enzyme demonstrated to be critical for tumor spread. A site on laminin, containing the amino acid sequence SIKVAV, has been identified which when injected intravenously with B16F10 melanoma cells, causes an increase in the number of colonies on the surface of the lungs. This peptide does not affect tumor cell arrest in the vasculature or the immune system. It does promote angiogenesis in various in vitro and in vivo models, thereby facilitating tumor cell survival.When a complex mixture of laminin-enriched basement membrane components (Matrigel) is coinjected with tumor cells subcutaneously, tumor incidence and growth increases. Various tumor cell lines and primary isolates, which previously could not form tumors in mice, can be induced to grow rapidly in the presence of Matrigel. Slowly growing tumors or arrested tumors can also be induced to grow more quickly with additional injections of Matrigel. When an SIKVAV-containing synthetic peptide is coinjected with B16F10 tumor cells and Matrigel subcutaneously in mice, larger tumors are formed than that observed with either Matrigel or cells alone. Such studies define the role of laminin in tumor growth and spread and generate new models for studying therapeutic agents. Of particular interest is the ability to grow primary isolates which generally do not grow in mice.     

健脾补土法对大鼠脑缺血再灌注后层黏连蛋白降解的影响

目的探讨健脾补土法对大鼠脑缺血再灌注后神经细胞周围层黏连蛋白(LN)的降解机制及其脑保护作用。方法 38只大鼠随机分为:假手术组8只,模型组10只,健脾补土传统汤剂组10只,健脾补土超微剂型组10只,大脑中动脉栓塞再通法建立脑缺血再灌注模型。进行神经功能症状评分,脑组织病理形态学观察,采用TUNEL法检测凋亡神经元,免疫组织化学法检测LN和基质金属蛋白酶9(MMP-9)阳性表达。结果与假手术组比较,模型组神经功能症状评分、细胞凋亡指数、MMP-9阳性细胞表达数明显升高,LN表达明显降低(P0.01)。与模型组比较,健脾补土传统汤剂组和健脾补土超微剂型组神经功能症状评分、细胞凋亡指数、MMP-9阳性细胞表达数明显降低,LN表达明显升高(P0.05,P0.01)。结论 LN降解在脑缺血再灌注损伤中起重要作用,健脾补土法可能通过抑制MMP-9和减少LN降解减轻缺血再灌注所致神经元损伤。     

层黏连蛋白及其受体在胃癌中的表达及其与侵袭和转移的关系

目的 :探讨层黏连蛋白 (LN)和LN受体 (LN R)的表达与胃癌侵袭和转移的关系。方法 :应用免疫组织化学S P法检测 68例胃癌组织中LN和LN R的表达。结果 :LN在有淋巴结转移组中阳性表达率明显低于无转移组 ,P <0 0 1;LN在其他各组中的表达差异无统计学意义 ,P >0 0 5 ;LN R的阳性表达率有随肿瘤分化水平的降低、浸润深度的增加而增高 ,P <0 0 1;淋巴结转移组中的LN R表达明显高于无淋巴结转移组 ,P <0 0 0 1。结论 :LN的低表达与肿瘤的转移有关 ,LN R的高表达与肿瘤分化、侵袭和转移的关系十分密切。LN和LN R可作为胃癌进展的重要生物学指标之一。     

Integrin α3β1 as a breast cancer target

Introduction: Integrin receptors for cell adhesion to the extracellular matrix have important roles in all stages of cancer progression and metastasis. Since the integrin family was discovered in the early 1980's, many studies have identified critical adhesion and signaling functions for integrins expressed on tumor cells, endothelial cells and other cell types of the tumor microenvironment, in controlling proliferation, survival, migration and angiogenesis. In recent years, the laminin-binding integrin α3β1 has emerged as a potentially promising anti-cancer target on breast cancer cells.

Areas covered: Studies from the past decade that implicate integrins as promising anti-cancer targets and the development of integrin antagonists as anti-cancer therapeutics. Recent preclinical studies that have identified the laminin-binding integrin α3β1 as an appealing anti-cancer target and the knowledge gaps that must be closed to fully exploit this integrin as a therapeutic target for breast cancer.

Expert opinion: Although the tumor-promoting functions of α3β1 implicate this integrin as a promising therapeutic target on breast cancer cells, successful exploitation of this integrin as an anti-cancer target will require a better understanding of the molecular mechanisms whereby it regulates specific tumor cell behaviors and the identification of the most appropriate α3β1 functions to antagonize on breast cancer cells.     

乳腺癌层粘连蛋白的免疫组织化学研究

本研究应用层粘连蛋白（ＬＮ）抗体，对２７例乳腺癌、５例乳腺良性病变进行了免疫组织化学研究。结果发现乳腺良性病变时，ＬＮ以均匀完整的线型阳性反应显示在乳腺导管及小叶基膜处。乳腺癌时，ＬＮ的染色表现为癌细胞胞浆内弥漫状阳性反应。２７例乳腺癌中，癌细胞ＬＮ染色强度不同，伴有转移的乳腺癌ＬＮ染色多数较强，强度在＋＋～的为７／１２（５８．３％）；不伴有转移的病例，ＬＮ染色多数较浅或为阴性，强度在＋＋～＋＋＋的病例为３／１５（２０％）。说明癌细胞内源性ＬＮ染色强弱与肿瘤转移密切相关，内源性ＬＮ的合成可能改变肿瘤细胞的浸润活性。